← Leaderboards
Marcus Laird Forrest
University Of Kansas Lawrence
$3,294,230
Attributed
$4,223,576
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $881.5K · FY2007–22$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$3,223,576 · 8
FDA$1,000,000 · 1
By mechanism
R01$1,435,536 · 1
R21$1,075,408 · 3
U01$1,000,000 · 1
R41$395,595 · 1
P20$317,037 · 3
Top collaborators
- Charles R Middaugh3 shared
- Christian Schoneich3 shared
- Aaron Smalter Hall3 shared
- Thomas J Tolbert3 shared
- David Volkin3 shared
- Brandon James Dekosky1 shared
Most similar at University Of Kansas Lawrence
Same institution · by research overlap
- Cory Berkland$3,518,234
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposPropertyTumorRodentMalignant NeoplasmsPharmaceutical PreparationsToxic EffectInnovationAnimalsAntineoplastic AgentsSiteDoseResearch PersonnelBiologicalIn VivoImageIn VitroNovel TherapeuticsEngineeringCancer CellBaseBlood VesselsPlasmaUptake
Grant awards (19)
Development of a tumor-retentive immunostimulant as adjunct therapy for solid tumor cancers$395,595
R41 · FY2022 · CA · contact PI
Mitochondria targeting for Alzheimer's Disease$227,250
R21 · FY2022 · AG · contact PI
Mitochondria targeting for Alzheimer's Disease$58,414
R21 · FY2022 · AG · contact PI
Mitochondria targeting for Alzheimer's Disease$189,375
R21 · FY2021 · AG · contact PI
Mitochondria targeting for Alzheimer's Disease$35,485
R21 · FY2021 · AG · contact PI
Comprehensive molecular and functional analyses of anti-HIV-1 broadly neutralizing antibody repertoires$192,025
R21 · FY2020 · AI · contact PI
Biomaterials for treatment of head and neck cancer$284,554
R01 · FY2017 · CA · contact PI
Biomaterials for treatment of head and neck cancer$284,554
R01 · FY2016 · CA · contact PI
Development of an Integrated Mathematical Model for Comparative Characterization of Complex Molecule$200,000
U01 · FY2016 · FD
Biomaterials for treatment of head and neck cancer$289,331
R01 · FY2015 · CA · contact PI
Development of an Integrated Mathematical Model for Comparative Characterization of Complex Molecule$200,000
U01 · FY2015 · FD
Development of an Integrated Mathematical Model for Comparative Characterization of Complex Molecule$600,000
U01 · FY2014 · FD
Biomaterials for treatment of head and neck cancer$281,488
R01 · FY2014 · CA · contact PI
Biomaterials for treatment of head and neck cancer$295,609
R01 · FY2013 · CA · contact PI
Targeted polymeric nanocarriers for combination therapy of metastatic prostate ca$208,389
R21 · FY2009 · CA · contact PI
NANOENCAPSULATED SIGNAL TRANSDUCTION INHIBITORS FOR BREAST CANCER$106,097
P20 · FY2009 · RR · contact PI
Targeted polymeric nanocarriers for combination therapy of prostate cancer$164,470
R21 · FY2008 · CA · contact PI
NANOENCAPSULATED SIGNAL TRANSDUCTION INHIBITORS FOR BREAST CANCER$155,084
P20 · FY2008 · RR · contact PI
NANOENCAPSULATED SIGNAL TRANSDUCTION INHIBITORS FOR BREAST CANCER$55,856
P20 · FY2007 · RR · contact PI